US drugmaker Pfizer is becoming more confident about the current year. With a good run, the group raised the bottom line growth forecast when delivering the third-quarter numbers and also raised its adjusted earnings per share forecast.
Third-quarter results showed commercial strength in many areas of the business, but it was somewhat overshadowed by the strong performance last year, Chief Financial Officer David Denton said Tuesday in New York. Also, Pfizer is facing some headwinds from the strong dollar. Overall, the group performed better than expected by analysts.
In terms of sales, Pfizer now expects at least $99.5 billion in 2022 instead of $98 billion previously. The maximum range is unchanged at $102 billion. One of the drivers of growth is again Comirnaty, a vaccine against Covid-19 developed in collaboration with Biontech. Sales forecasts were increased by $2 billion to approximately $34 billion. Adjusted earnings per share should be between $6.4 and $6.5 for the full year, up from $6.3 to $6.45 previously.
Sylvia Plath writes for Social Post News, covering news, politics, business, technology, sport, entertainment, and lifestyle. She focuses on clear, reliable reporting and useful information, helping readers stay informed about current events, emerging trends, and stories that matter.
More Stories
Colorado Springs Could Gain Second Stop on Colorado’s Front Range Passenger Rail Line Under New Draft Plan
Amazon Prime Day Deals Still Available: More Than 130 Discounts Remain on Apple, Oura, Sony and Other Top Brands
Wealthy families take more risks when it comes to money.